Vertaling van "any drug applications that have " (Nederlands → Frans) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

patients has to do with the fact that on the one hand, psychological suffering is less tangible than somatic suffering and that, on the other hand, any injuries that need looking after have been caused by the patients themselves.
certain malaise face à ces patients tient au fait que, d’une part, la souffrance psychique est moins tangible que la souffrance somatique et que, d’autre part, les éventuelles lésions à soigner ont été provoquées par le patient lui-même.

“In any case, our observations have no doubt a great social value: in spite of the fact that Belgium has a widespread offer of medical care for emotional problems and mental disorders, it is clear from the ESEMeD data that the resources are not used optimally.
« En tout cas, nos observations ont sans conteste une grande valeur sociale: malgré le fait que la Belgique dispose d’une importante offre de soins pour les problèmes émotionnels et les troubles mentaux, les données ESEMeD révèlent que les ressources ne sont pas utilisées de manière optimale.

Finally, the EFSA observes that there is unlikely to be any interaction between glucuronolactone and caffeine, taurine, alcohol or the effects of physical effort. Yet, it points out that a number of potential interactions between taurine and caffeine have not been examined (EFSA, 2009).
Enfin, l’EFSA signale qu’il est improbable que la glucuronolactone présente une quelconque interaction avec la caféine, la taurine, l’alcool ou les effets de l’exercice mais signale néanmoins qu’un certain nombre d’interactions possibles entre la taurine et la caféine n’ont pas été étudiées (EFSA, 2009).

The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.
The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.

Luckily for Shawn, Novartis wants to provide Glivec to patients who would otherwise not have access to it. Through its Glivec International Patient Assistance Program (GIPAP), Novartis has made it possible for the young South African to have a continual supply of the drug that has saved his life.
Avec sa campagne mondiale d’assistance aux malades (Glivec International Patient Assistance Program GIPAP), Novartis a permis au jeune Sud-Africain de recevoir de manière ininterrompue le médicament qui a sauvé sa vie.

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

Novartis has several other drugs in its pipeline that have promise for patients with unmet needs.
Novartis possède plusieurs autres médicaments dans son pipeline qui répondent aux besoins non satisfaits des malades.